Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 24, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 500,000 ordinary shares of 25 pence each.
- Purchase Date: August 23, 2005.
- Price per Share: 1,323.737 pence.
- Treasury Shares Held: 107,123,000 (post-transaction).
- Shares in Issue: 5,837,124,117 (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 25, 2005. The company intends to hold the repurchased shares in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 500,000 share repurchase based on the disclosed price of 1,323.737 pence per share.
- Confirm the updated total share count (5,837,124,117 in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the share buyback authority granted.